Become a DETERMINE partner
The DETERMINE precision medicine trial enables the valuation of licensed targeted cancer drugs in unlicensed cancer indications. We are seeking additional licensed targeted drugs from pharmaceutical and biotech companies and welcome enquiries about being included in the study.
Benefits of becoming a partner
New and existing DETERMINE partnerships with industry and academic collaborators are supported by the business development team at Cancer Research Horizons, Cancer Research UK's translation and commercialisation arm.
As a commercial partner and provider of DETERMINE treatment arms, you’ll benefit from:
- opportunities to generate a rich translational data package that can help optimise biomarker selection of patients
- chances to streamline compassionate use requests into a structured access mechanism with associated data collection
- formalised data collection to support specialist commissioning and reimbursement strategies
- single point of access to a trial with over 20 UK sites with the option to expand to European sites through the PRIME-ROSE consortium
- dedicated business development contact and single contract to gain access to a trial with over 20 site
About DETERMINE
The trial is expected to recruit 300-400 patients across the UK through existing national screening programmes. This will take place over five years with a two-year follow-up period. Treatment arms will be added on a continual basis, with each arm to be evaluated through regular interim analyses.
DETERMINE is delivered through the Experimental Cancer Medicine Centres Network, with 29 adult and paediatric sites across the UK. As the trial sponsor, the Cancer Research UK Centre for Drug Development is responsible for all aspects of management and delivery of DETERMINE, acting as the central contact point for our partners.
What to expect
Our partners
Roche
Founding pharma partner Roche Products Ltd (UK) joined us in December 2021. Roche is providing funding, drug and genomic tests for the initial five treatment arms in this study. They have provided seven of their targeted therapies to be evaluated.
Novartis
Novartis joined us as our second partner in December 2022 and has provided one of their targeted therapies for evaluation. They will support their treatment arm with funding, drug and genomic tests.
Other things you may be interested in
PRIME-ROSE
DETERMINE is part of PRIME-ROSE, which aims to broaden patient access to a wider range of innovative precision cancer medicine treatments by connecting similar clinical trials.
Centre for Drug Development (CDD)
CDD partners with academics, biotech, and pharma to deliver early-phase clinical trials.
Experimental Cancer Medicine Centres Network (ECMC)
DETERMINE is delivered through the ECMC network, which supports Cancer Research UK, industry, other funders and partners with early phase trials.